Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as ...
Translate Bio, Inc. is an early-clinical-stage biotechnology company developing mRNA therapeutics and vaccines targeting protein or gene dysfunction and infectious diseases respectively. Translate Bio ...
Zacks Investment Research on MSN
Palisade Bio (PALI) upgraded to buy: Here's what you should know
Palisade Bio, Inc. (PALI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
With strong 1-year returns and upside potential, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list of the 12 best ...
Top-line results from the MINDFuL phase 2 trial in Alzheimer’s expected in the second half of June. Presented baseline demographics and disease profiles of participants in the MINDFuL phase II study ...
Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations through 2027. Upstream Bio, Inc. announced the completion of patient enrollment in ...
ImmunityBio, Inc. (NASDAQ:IBRX) is among the best NASDAQ stocks under $10 to buy. On December 15, Edward Tenthoff, an analyst ...
NEW YORK, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, today announced the ...
Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...
If you want to know who really controls Climb Bio, Inc. (NASDAQ:CLYM), then you'll have to look at the makeup of its share registry. With 54% stake, private equity firms possess the maximum shares in ...
ACET is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of ACET shares has decreased $0.01 since the market last closed. This is a 1.20% ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--Teal Bio, Inc., a medical device startup revolutionizing respiratory protection, today announced it has raised a $2.45 million Series A financing led by Caligan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback